
As we all know, the blood and biotherapies supply network requires cross-functional collaboration, quality control, safety, security and efficiency. This includes accurate and complete labeling of all blood and biotherapy products.
Digital connectivity supports these priorities. But what if systems go dark?
A digital darkness event refers to a “sudden, widespread loss of access to electronic systems and patient information. These events can stem from cyberattacks, natural disasters, power failures, vendor outages, software errors or internal system failures,” according to ECRI, a global health care quality and safety nonprofit organization.1
Cyber outages impact patient care, safety and financial stability. In recent years, there have been several such high-profile events. For example:
A plan to maintain optimal blood product labeling is an essential part of disaster preparedness. The table below shows considerations related to automated labeling. (These are not comprehensive; they are examples offered to raise awareness.)

Accurate blood product labeling is essential during an emergency. Manual labeling procedures are one option during digital downtime. However, stand-alone automated labeling solutions offer an alternative. Blood collection can carry on with the benefits of efficient, accurate labeling during periods of digital darkness.
Jeff Kriozere is vice president and general manager, Digi-Trax Healthcare Division, FineLine Technologies Inc.
PREVIOUS STORY
Strengthening Blood Safety Systems in ColombiaBACK TO ISSUE
May 2026
Transfusion is AABB’s scholarly, peer-reviewed monthly journal, publishing the latest on technological advances, clinical research and controversial issues related to transfusion medicine, blood banking, biotherapies and tissue transplantation. Access of Transfusion is free to all AABB members.
Learn More About Transfusion Journal
Keep abreast of what's happening in the field of biotherapies with CellSource - AABB's monthly update on the latest biotherapies news.
To submit news about the blood and biotherapies field to AABB, please email news@aabb.org.
President
Jose Cancelas, MD, PhD, CABP
Chief Executive Officer
Debra Ben Avram, FASAE, CAE
Chief Communications and Engagement Officer
Julia Zimmerman
Director of Marketing and Communications
Jay Lewis, MPH
Managing Editor
Kendra Y. Mims, MFA
Senior Communications Manager
Drew Case
AABB News
(ISSN 1523939X) is published monthly, except for the combined November/December issue for the members of AABB; 4550 Montgomery Avenue; Suite 700 North Tower; Bethesda, MD 20814.
AABB is an international, not-for-profit association representing individuals and institutions involved in transfusion medicine, cellular therapies and patient blood management. The association is committed to improving health by developing and delivering standards, accreditation and educational programs that focus on optimizing patient and donor care and safety.
+1.301.907.6977
Email: news@aabb.org
Website: www.aabb.org
Copyright 2025 by AABB.
Views and opinions expressed in AABB News are not necessarily endorsed by AABB unless expressly stated.
Notice to Copiers: Reproduction in whole or part is strictly prohibited unless written permission has been granted by the publisher. AABB members need not obtain prior permission if proper credit is given.
